STEP Levels Are Unchanged in Pre-Frontal Cortex and Associative Striatum in Post-Mortem Human Brain Samples from Subjects with Schizophrenia, Bipolar Disorder and Major Depressive Disorder

Increased protein levels of striatal-enriched tyrosine phosphatase (STEP) have recently been reported in postmortem schizophrenic cortex. The present study sought to replicate this finding in a separate cohort of postmortem samples and to extend observations to striatum, including subjects with bipolar disorder and major depressive disorder in the analysis. No statistically significant changes between disease and control subjects were found in STEP mRNA or protein levels in dorsolateral prefrontal cortex or associative striatum. Although samples were matched for several covariates, postmortem interval correlated negatively with STEP protein levels, emphasizing the importance of including these analyses in postmortem studies.

[1]  Kazuya Iwamoto,et al.  Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. , 2005, Human molecular genetics.

[2]  K. Nikolich,et al.  Regulation of NMDA receptor trafficking and function by striatal‐enriched tyrosine phosphatase (STEP) , 2006, The European journal of neuroscience.

[3]  P. Schofield,et al.  Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia , 2012, Molecular Psychiatry.

[4]  D. Lewis,et al.  NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. , 2012, Schizophrenia bulletin.

[5]  V. Haroutunian,et al.  The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications , 2012, Translational Psychiatry.

[6]  HighWire Press.  The journal of neuroscience : the official journal of the Society for Neuroscience. , 1981 .

[7]  D. Lewis,et al.  GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia , 2011, Neural plasticity.

[8]  J. Glausier,et al.  Lower Glutamic Acid Decarboxylase 65-kDa Isoform Messenger RNA and Protein Levels in the Prefrontal Cortex in Schizoaffective Disorder but Not Schizophrenia , 2015, Biological Psychiatry.

[9]  David A Lewis,et al.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. , 2008, The American journal of psychiatry.

[10]  A. Sampson,et al.  Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. , 2011, The American journal of psychiatry.

[11]  M. Webster,et al.  Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. , 2010, The American journal of psychiatry.

[12]  H. Lane,et al.  Glutamate signaling in the pathophysiology and therapy of schizophrenia , 2012, Pharmacology Biochemistry and Behavior.

[13]  H. M. Morris,et al.  GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. , 2011, The international journal of neuropsychopharmacology.

[14]  T. Steckler,et al.  NMDA receptors, cognition and schizophrenia – Testing the validity of the NMDA receptor hypofunction hypothesis , 2012, Neuropharmacology.

[15]  S. Akbarian.  MOLECULAR DETERMINANTS OF DYSREGULATED GABAERGIC GENE EXPRESSION IN THE PREFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA , 2010, Schizophrenia Research.

[16]  P. Wahle,et al.  Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  M. Kuhn,et al.  Downstream effects of striatal-enriched protein tyrosine phosphatase reduction on RNA expression in vivo and in vitro , 2014, Neuroscience.

[18]  G. Collingridge,et al.  The Tyrosine Phosphatase STEP Mediates AMPA Receptor Endocytosis after Metabotropic Glutamate Receptor Stimulation , 2008, The Journal of Neuroscience.